MUSCLE RELAXANT AND ANALGESIC CAPLETS TABLET

Valsts: Kanāda

Valoda: angļu

Klimata pārmaiņas: Health Canada

Nopērc to tagad

Produkta apraksts Produkta apraksts (SPC)
01-02-2010

Aktīvā sastāvdaļa:

IBUPROFEN; METHOCARBAMOL

Pieejams no:

INTERNATIONAL PHARMACEUTICAL GENERICS LTD

ATĶ kods:

M03BA53

SNN (starptautisko nepatentēto nosaukumu):

METHOCARBAMOL, COMBINATIONS EXCL PSYCHOLEPTICS

Deva:

200MG; 500MG

Zāļu forma:

TABLET

Kompozīcija:

IBUPROFEN 200MG; METHOCARBAMOL 500MG

Ievadīšanas:

ORAL

Vienības iepakojumā:

100

Receptes veids:

OTC

Ārstniecības joma:

CENTRALLY ACTING SKELETAL MUSCLE RELAXANTS

Produktu pārskats:

Active ingredient group (AIG) number: 0248961001; AHFS:

Autorizācija statuss:

CANCELLED PRE MARKET

Autorizācija datums:

2017-06-13

Produkta apraksts

                                1 | P a g e
PRODUCT MONOGRAPH
MUSCLE RELAXANT & ANALGESIC CAPLETS
500 MG METHOCARBAMOL AND 200 MG IBUPROFEN TABLETS
THERAPEUTIC CLASSIFICATION
MUSCLE RELAXANT / ANALGESIC
INTERNATIONAL PHARMACEUTICAL GENERICS LTD.,
Date of Preparation:
30 Malta Avenue, Suite 2408
February 01, 2010
Brampton, ON
L6Y 4S5
Control#: 135919
2 | P a g e
TABLE
OF CONTENTS
Clinical
Pharmacology..............................................................................................................................3
Indications:................................................................................................................................................7
Contraindications
......................................................................................................................................8
Warnings:..................................................................................................................................................8
Precautions..............................................................................................................................................12
Drug Interactions
....................................................................................................................................13
Adverse Reactions
..................................................................................................................................15
Symptoms and Treatment of
Overdose...................................................................................................17
Dosage and
Administration.....................................................................................................................18
Pharmaceutical
Information....................................................................................................................19
Composition:...........................................................................................................................................21
Availability of Dosage
Forms............
                                
                                Izlasiet visu dokumentu